285 related articles for article (PubMed ID: 18473857)
21. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
[TBL] [Abstract][Full Text] [Related]
22. Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo.
Lo YL; Liu Y; Tsai JC
Biomed Pharmacother; 2013 May; 67(4):261-7. PubMed ID: 23540284
[TBL] [Abstract][Full Text] [Related]
23. Antisense- and siRNA-mediated inhibition of the anti-apoptotic gene Bcl-xL for chemosensitization of bladder cancer cells.
Rieger C; Huebner D; Temme A; Wirth MP; Fuessel S
Int J Oncol; 2015 Sep; 47(3):1121-30. PubMed ID: 26201840
[TBL] [Abstract][Full Text] [Related]
24. Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells.
Normanno N; Tortora G; De Luca A; Pomatico G; Casamassimi A; Agrawal S; Mendelsohn J; Bianco AR; Ciardiello F
Oncol Rep; 1999; 6(5):1105-9. PubMed ID: 10425310
[TBL] [Abstract][Full Text] [Related]
25. Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapy.
Gleixner KV; Mayerhofer M; Vales A; Gruze A; Hörmann G; Cerny-Reiterer S; Lackner E; Hadzijusufovic E; Herrmann H; Iyer AK; Krauth MT; Pickl WF; Marian B; Panzer-Grümayer R; Sillaber C; Maeda H; Zielinski C; Valent P
Curr Cancer Drug Targets; 2009 Aug; 9(5):675-89. PubMed ID: 19508170
[TBL] [Abstract][Full Text] [Related]
26. Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis.
Siegmund D; Hadwiger P; Pfizenmaier K; Vornlocher HP; Wajant H
Mol Med; 2002 Nov; 8(11):725-32. PubMed ID: 12520089
[TBL] [Abstract][Full Text] [Related]
27. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide.
Mizutani Y; Fukumoto M; Bonavida B; Yoshida O
Cancer; 1994 Nov; 74(9):2546-54. PubMed ID: 7923012
[TBL] [Abstract][Full Text] [Related]
28. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
Spänkuch B; Kurunci-Csacsko E; Kaufmann M; Strebhardt K
Oncogene; 2007 Aug; 26(39):5793-807. PubMed ID: 17369857
[TBL] [Abstract][Full Text] [Related]
29. Tumor growth inhibition in vivo and G2/M cell cycle arrest induced by antisense oligodeoxynucleotide targeting thymidylate synthase.
Berg RW; Werner M; Ferguson PJ; Postenka C; Vincent M; Koropatnick DJ; Behrend E
J Pharmacol Exp Ther; 2001 Aug; 298(2):477-84. PubMed ID: 11454908
[TBL] [Abstract][Full Text] [Related]
30. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-Based Combinatorial Cancer Therapy: Effects of MicroRNAs on the Efficacy of Anti-Cancer Therapies.
Seo HA; Moeng S; Sim S; Kuh HJ; Choi SY; Park JK
Cells; 2019 Dec; 9(1):. PubMed ID: 31861937
[TBL] [Abstract][Full Text] [Related]
32. Novel anticancer agents in clinical development.
Adjei AA; Rowinsky EK
Cancer Biol Ther; 2003; 2(4 Suppl 1):S5-15. PubMed ID: 14508076
[TBL] [Abstract][Full Text] [Related]
33. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.
Liu T; Liu PY; Tee AE; Haber M; Norris MD; Gleave ME; Marshall GM
Eur J Cancer; 2009 Jul; 45(10):1846-54. PubMed ID: 19342222
[TBL] [Abstract][Full Text] [Related]
34. Antisense anticancer oligonucleotide therapeutics.
Wang H; Prasad G; Buolamwini JK; Zhang R
Curr Cancer Drug Targets; 2001 Nov; 1(3):177-96. PubMed ID: 12188878
[TBL] [Abstract][Full Text] [Related]
35. Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms.
Wang H; Oliver P; Zhang Z; Agrawal S; Zhang R
Ann N Y Acad Sci; 2003 Dec; 1002():217-35. PubMed ID: 14751837
[TBL] [Abstract][Full Text] [Related]
36. Strategies on the development of small molecule anticancer drugs for targeted therapy.
Lu YH; Gao XQ; Wu M; Zhang-Negrerie D; Gao Q
Mini Rev Med Chem; 2011 Jun; 11(7):611-24. PubMed ID: 21699492
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
38. Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: progress and therapeutic potential.
Olie RA; Zangemeister-Wittke U
Drug Resist Updat; 2001 Feb; 4(1):9-15. PubMed ID: 11512155
[TBL] [Abstract][Full Text] [Related]
39. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
40. Antisense molecules for targeted cancer therapy.
Wacheck V; Zangemeister-Wittke U
Crit Rev Oncol Hematol; 2006 Jul; 59(1):65-73. PubMed ID: 16750913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
